Treatment of Chronic Parkinson's Disease with Controlled-Release Carbidopa/Levodopa

Jerry L. Morris, J. Thomas Hutton, Gustavo C. Roman, Susan C. Imke, Jeffrey W. Elias

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


Controlled-release carbidopa/levodopa 50/200 (SINEMET CR) and standard carbidopa/levodopa (SINEMET 25/100) were compared in a double-blind, six-month, crossover study involving 21 patients with chronic Parkinson's disease and motor response fluctuations. Daily dosage frequency was significantly reduced with SINEMET CR compared with SINEMET 25/100, while the daily amount of levodopa required with SINEMET CR was significantly greater. No significant differences in disability ratings, motor response fluctuations, or safety were detected during double-blind conditions. In the open-label, dose-finding phase of the study, SINEMET CR was superior to standard SINEMET 25/100 in patient ratings of percent 'on' time (good motor function), clinical assessments of motor function, and activities of daily living. This finding resulted from a depreciation of the value of the 'old drug' rather than an overestimation of the value of the experimental drug. This double-blind study also suggested that elderly male patients with Parkinson's disease derived the greatest benefit from SINEMET CR.

Original languageEnglish (US)
Pages (from-to)861-864
Number of pages4
JournalArchives of neurology
Issue number8
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology


Dive into the research topics of 'Treatment of Chronic Parkinson's Disease with Controlled-Release Carbidopa/Levodopa'. Together they form a unique fingerprint.

Cite this